Amsterdam — Oct. 19-21, 2026 — Dr. David Burkhart to chair Vaccine Delivery Workshop; Dr. Juhienah Khalaf to give joint presentation with SPI Pharma to highlight partnering and global access to innovative adjuvants
Inimmune today announced that Dr. David Burkhart, Chief Executive Officer, will chair the Vaccine Delivery Workshop at the World Vaccine Congress Europe, taking place October 19–21, 2026, in Amsterdam.
On Wednesday, October 21, Dr. Juhienah Khalaf, Inimmune’s Director of Adjuvant Portfolio, will co-present with Peter Tygesen, Director of Business Development at SPI Pharma, on **“Innovative Adjuvants for Advancing Global Health.”** Their presentation will highlight how the Inimmune–SPI Pharma partnership is providing vaccine developers across the globe access to Inimmune’s next-generation adjuvant technologies.
Vaccines remain among the most powerful tools for preventing disease and protecting human health. Formulation science plays a critical role in their success, influencing antigen stability, delivery and the strength and duration of immune responses. Integrating antigens, adjuvants and delivery technologies is essential to optimizing vaccine efficacy, safety and tolerability.
“Developing better vaccines requires bringing adjuvant selection and formulation science together from the outset,” said Dr. Burkhart. “Through our extensive adjuvant portfolio, formulation expertise and partnership with SPI Pharma, we are equipping vaccine developers worldwide with tools to advance more effective, safer vaccines.”
Inimmune’s portfolio includes synthetic TLR4 and TLR7/8 agonists and combination adjuvant systems incorporating emulsions, liposomes, alum and saponins. Together, Inimmune and SPI Pharma are expanding access to advanced adjuvant systems, helping developers tailor immune responses to specific vaccine needs and advance the next generation of vaccines for human health.
